Homepage Top Section2

Libtayo is a fully-human monoclonal antibody that targets the immune checkpoint receptor PD-1 (programmed cell death protein-1), and is claimed to be the first and only treatment specifically

In November 2014, Janssen signed an exclusive worldwide collaboration and license agreement with Geron for the development and commercialization of imetelstat in oncology, including hematologic myeloid malignancies. Janssen

Based in Boston of Massachusetts, Syntimmune is engaged in the development of differentiated drug candidates in a range of autoimmune diseases. As per terms of the deal, Alexion

The acquisition of NextWave will allow Tris Pharma to expand its products for the treatment of patients with attention deficit hyperactivity disorder (ADHD). ADHD is a common neurodevelopmental

ROP is a rare and potentially blinding resulted due to abnormal development of retinal blood vessels in premature babies. The company has presented data from a Rainbow phase

OBI-3424 is a DNA alkylating cancer therapeutic agent that targets aldo-keto reductase 1C3 (AKR1C3) overexpressing cancers. AKR1C3 overexpression has been known to be found in various treatment-resistant and

The KUBio biomanufacturing facility for BeiGene will be located in Guangzhou in the Chinese province Guangdong, where other biotech firms are setting up operations, said GE. It will

Alopecia areata is an autoimmune disease evidenced by hair loss and often linked with profound psychological consequences. The PF-06651600 is an oral JAK 3 inhibitor, while PF-06700841 is a

Keytruda is the first anti-PD-1 therapy approved in combination with chemotherapy in Europe for first-line use in patients with metastatic NSCLC. The European approval is for the first-line